Short Interest in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Increases By 8.1%

Amicus Therapeutics, Inc. (NASDAQ:FOLD) was the target of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 35,950,000 shares, an increase of 8.1% from the January 15th total of 33,260,000 shares. Approximately 14.5% of the shares of the company are short sold. Based on an average trading volume of 3,120,000 shares, the short-interest ratio is currently 11.5 days.

In other news, COO Bradley L. Campbell sold 2,500 shares of the firm’s stock in a transaction on Thursday, January 9th. The shares were sold at an average price of $10.01, for a total value of $25,025.00. Following the sale, the chief operating officer now owns 347,695 shares in the company, valued at $3,480,426.95. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Bradley L. Campbell sold 22,127 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $9.58, for a total transaction of $211,976.66. Following the completion of the sale, the chief operating officer now owns 253,987 shares in the company, valued at approximately $2,433,195.46. The disclosure for this sale can be found here. In the last 90 days, insiders sold 310,637 shares of company stock worth $3,103,288. 2.50% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of FOLD. BlackRock Inc. boosted its stake in Amicus Therapeutics by 10.8% during the second quarter. BlackRock Inc. now owns 18,580,413 shares of the biopharmaceutical company’s stock worth $231,885,000 after buying an additional 1,805,661 shares in the last quarter. State Street Corp lifted its holdings in shares of Amicus Therapeutics by 18.2% during the third quarter. State Street Corp now owns 11,581,181 shares of the biopharmaceutical company’s stock valued at $92,881,000 after acquiring an additional 1,783,202 shares during the period. Peregrine Capital Management LLC bought a new position in shares of Amicus Therapeutics during the fourth quarter valued at $12,229,000. Phoenix Holdings Ltd. bought a new position in shares of Amicus Therapeutics during the third quarter valued at $8,960,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Amicus Therapeutics by 42.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,372,952 shares of the biopharmaceutical company’s stock valued at $32,852,000 after acquiring an additional 1,007,617 shares during the period.

A number of equities research analysts have weighed in on FOLD shares. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Amicus Therapeutics in a research note on Thursday, January 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price target (up previously from $19.00) on shares of Amicus Therapeutics in a research note on Tuesday, February 4th. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday. Robert W. Baird reiterated a “buy” rating and set a $20.00 price target on shares of Amicus Therapeutics in a research note on Thursday, January 9th. Finally, ValuEngine upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, January 7th. Eight analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $19.03.

FOLD traded up $0.01 during trading on Friday, reaching $10.98. 2,120,285 shares of the company’s stock were exchanged. Amicus Therapeutics has a fifty-two week low of $7.11 and a fifty-two week high of $14.61. The business has a 50 day moving average price of $9.73 and a 200 day moving average price of $9.61.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Further Reading: What does cost of debt say about a company’s financial health?

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit